The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in Korea.

Jeon, Ha-Lim; Kim, Seoyoung C; Park, So-Hee; Shin, Ju-Young

Jeon, Ha-Lim; Kim, Seoyoung C; Park, So-Hee; Shin, Ju-Young.

Affiliation

Jeon HL; School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
Kim SC; Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA; Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Park SH; School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea.
Shin JY; School of Pharmacy, Sungkyunkwan University, Suwon, Republic of Korea; Samsung Advanced Institute for Health Sciences & Technology (SAIHST), Sungkyunkwan University, Seoul, Republic of Korea. Electronic address: shin.jy@skku.edu.

Semin Arthritis Rheum ; 51(5): 989-995, 2021 10.

Article in En | MEDLINE | ID: mdl-34403814

Subject(s)
Key words

Comparative safety; Serious infection; Tocilizumab; Tumor necrosis factor inhibitors

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Antirheumatic Agents / Antibodies, Monoclonal, Humanized / Infections Type of study: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Country/Region as subject: Asia Language: En Journal: Semin Arthritis Rheum Year: 2021 Document type: Article Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google